On Friday, Replimune Group Inc (NASDAQ: REPL) opened higher 3.93% from the last session, before settling in for the closing price of $5.35. Price fluctuations for REPL have ranged from $2.68 to $17.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -14.85%. Company’s average yearly earnings per share was noted 3.09% at the time writing. With a float of $63.82 million, this company’s outstanding shares have now reached $77.81 million.
Let’s determine the extent of company efficiency that accounts for 479 employees. In terms of profitability, gross margin is -192.19%, operating margin of -20019.16%, and the pretax margin is -19004.76%.
Replimune Group Inc (REPL) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Replimune Group Inc is 18.88%, while institutional ownership is 97.04%. The most recent insider transaction that took place on May 20 ’25, was worth 260,169. In this transaction Director of this company sold 32,279 shares at a rate of $8.06, taking the stock ownership to the 1,405,071 shares. Before that another transaction happened on May 20 ’25, when Company’s Chief Medical Officer sold 7,952 for $8.06, making the entire transaction worth $64,093. This insider now owns 146,933 shares in total.
Replimune Group Inc (REPL) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.68 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.74) by 0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.77 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 3.09% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 22.27% during the next five years compared to -14.85% drop over the previous five years of trading.
Replimune Group Inc (NASDAQ: REPL) Trading Performance Indicators
Check out the current performance indicators for Replimune Group Inc (REPL). In the past quarter, the stock posted a quick ratio of 6.94.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.38, a number that is poised to hit -0.77 in the next quarter and is forecasted to reach -1.75 in one year’s time.
Technical Analysis of Replimune Group Inc (REPL)
Looking closely at Replimune Group Inc (NASDAQ: REPL), its last 5-days average volume was 4.59 million, which is a jump from its year-to-date volume of 4.12 million. As of the previous 9 days, the stock’s Stochastic %D was 40.29%.
During the past 100 days, Replimune Group Inc’s (REPL) raw stochastic average was set at 27.27%, which indicates a significant decrease from 48.77% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.77 in the past 14 days, which was higher than the 0.72 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.26, while its 200-day Moving Average is $10.45. However, in the short run, Replimune Group Inc’s stock first resistance to watch stands at $5.82. Second resistance stands at $6.07. The third major resistance level sits at $6.31. If the price goes on to break the first support level at $5.33, it is likely to go to the next support level at $5.09. Should the price break the second support level, the third support level stands at $4.84.
Replimune Group Inc (NASDAQ: REPL) Key Stats
There are currently 78,056K shares outstanding in the company with a market cap of 433.99 million. Presently, the company’s annual sales total 0 K according to its annual income of -247,300 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -86,690 K.
